EPOR and neoplasm: The recombinant human erythropoietin competes with ephrin-B2 for binding to EPHB4, and therefore, the tumor progression might be mediated via EPO-induced phosphorylation of EPHB4 and subsequent activation of downstream signaling, independent of the EPOR (Gilreath and Rodgers, 2020).